How much does stem cell therapy for Parkinson's Disease cost? (2026)
The comparison dataset stores a Bulgaria planning observation of €3,000–€8,000 for treatment, compiled from cited public commercial sources. It is not a quotation from Stem Plus, and different products, doses, visits and inclusions must not be treated as equivalent. The stored registry query contains 70 Parkinson's Disease records. Registration does not mean that a study is recruiting, that a person is eligible, or that treatment and travel are free; verify the current record and sponsor-cost terms directly.
Parkinson's disease involves progressive loss and dysfunction of dopaminergic and other neural systems. Research includes pluripotent-stem-cell-derived dopaminergic progenitors intended for intracerebral transplantation, as well as unrelated MSC or exosome proposals. These products, routes and objectives are not interchangeable, and replacing cells does not automatically control the wider disease process.
What drives the cost for Parkinson's Disease
A same-day intravenous product cannot be priced or evaluated as equivalent to a neurosurgical cell-replacement trial. Request an itemised statement for product, surgery or administration, imaging, immunosuppression where applicable, monitoring, travel and long-term follow-up. Preserve access to established neurological care.
Cell-replacement programmes remain specialised clinical research and must establish identity, purity, dose, surgical delivery, tumour risk, graft survival and clinically meaningful function. Laboratory generation of dopamine-producing neurons supports a research hypothesis, not a commercial efficacy claim. The NINDS stem-cell research overview describes this work, while the FDA patient page states that regenerative medicine therapies are not approved in the United States for Parkinson's disease.
Parkinson's Disease cost by country — comparison (2026)
| Location | Indicative treatment cost | Regulation |
|---|---|---|
| Bulgaria (EU) · e.g. Stem Plus | €3,000–€8,000 | Verify provider and laboratory certificates |
| USA | €4,600–€46,000 | Non-EU; verify provider and product status |
| UK | €4,880–€49,000 | Non-EU; verify provider and product status |
| Germany | €11,000–€36,700 | EU member state; verify provider and product status |
| Switzerland | €20,000–€40,000 | Non-EU; verify provider and product status |
| Mexico | €3,000–€12,000 | Non-EU; verify provider and product status |
| India | €3,000–€8,000 | Non-EU; verify provider and product status |
| Serbia | €7,000–€31,000 | Non-EU; verify provider and product status |
| Turkey | €6,000–€18,000 | Non-EU; verify provider and product status |
| Thailand | €8,000–€20,000 | Non-EU; verify provider and product status |
| Panama | €15,000–€27,000 | Non-EU; verify provider and product status |
Price varies with cell type, dose, number of sessions, diagnostics, supportive care and follow-up. A lower range does not establish equivalent quality or outcome. Request a fixed written quote and verify the therapy and provider with the relevant authorities. Check registered trials before paying privately.
Parkinson's Disease cost — common questions
Why is Parkinson's Disease stem-cell treatment so much cheaper in Bulgaria?
The collected commercial ranges differ, but they may describe different products, doses, visits and inclusions. A lower quote does not establish equivalent quality, evidence or regulatory status.
Is a cheaper programme riskier?
Price alone cannot establish risk. Verify the exact treatment status, provider and manufacturing authorisations, product identity, release testing, adverse-event plan and primary evidence.
Does the price include travel and hotel?
The €3,000–€8,000 range covers the medical programme. Add flights, hotel and recovery with our calculator for your true all-in cost from your city.
Will I get a fixed quote, or an open-ended bill?
Ask for a written quotation after clinical review, with the exact product, inclusions, exclusions, cancellation terms and circumstances in which charges may change. A website estimate is not a binding quote.
Sources & further reading
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
- Open clinical trials for Parkinson's Disease (ClinicalTrials.gov) ↗
- Peer-reviewed research on PubMed ↗
- ISSCR patient guide — what to ask ↗
- FDA consumer warning on stem-cell therapies ↗
- EMA — advanced-therapy (ATMP) framework ↗
- Clinic perspective — Stem Plus on Parkinson's Disease ↗
Indicative ranges for planning, compiled from public market data; confirmed pricing follows a medical review. Not medical advice.